Pulmonary Fibrosis vs. COPD: A Detailed Comparison

TL;DR

• Pulmonary Fibrosis (PF) and COPD are both serious lung conditions that make breathing difficult, but they are very different diseases.
• PF scars and stiffens lung tissue, making it hard to expand your lungs. COPD damages the airways and air sacs, making it hard to push air out.
• They have different causes, different symptoms, and different treatment paths. Getting the right diagnosis matters enormously, because what helps one condition can be unhelpful, or even harmful, for the other.

‍

What Is Pulmonary Fibrosis?

Pulmonary Fibrosis is a lung disease in which healthy lung tissue is progressively replaced by scar tissue (fibrosis). As scarring builds up over time, your lungs become stiff and lose their ability to expand fully. This makes it increasingly difficult to breathe deeply and get enough oxygen into your blood.

The most common form is called Idiopathic Pulmonary Fibrosis (IPF). "Idiopathic" simply means doctors cannot pinpoint an exact cause. Global prevalence estimates range from 0.33 to 4.51 per 10,000 people, with incidence between 0.09 and 1.30 per 10,000 annually, making it a relatively rare but serious condition. IPF most commonly affects people over the age of 60.

Think of it this way: healthy lung tissue is like a soft sponge, flexible and airy. In Pulmonary Fibrosis, that sponge gradually hardens into something closer to leather. It cannot stretch, so every breath feels like a deliberate effort.

‍

What Is COPD?

Chronic Obstructive Pulmonary Disease (COPD) is an umbrella term for a group of progressive lung conditions, primarily chronic bronchitis and emphysema, that obstruct airflow out of the lungs. Rather than stiffening the lung tissue itself, COPD damages the airways and the tiny air sacs (alveoli) where oxygen exchange happens.

The World Health Organization (WHO) estimates that COPD affects over 300 million people globally, making it one of the leading causes of death worldwide. Smoking is the largest single risk factor: more than 70% of COPD cases occur in current or former smokers, though it is important to note that only 15–50% of smokers go on to develop COPD. Long-term exposure to air pollution, occupational dust and fumes, and a rare genetic condition called Alpha-1 Antitrypsin Deficiency also contribute to COPD risk.

If Pulmonary Fibrosis is a hardening sponge, COPD is a damaged bellows, the mechanism for pushing air out becomes weakened and obstructed, trapping stale air inside the lungs with each breath.

‍

How Are the Causes Different?

Understanding what caused your condition is the first step to managing it well.

Pulmonary Fibrosis causes include occupational exposure to dust and chemicals (such as silica, asbestos, or bird droppings), certain medications (including some chemotherapy drugs and heart medications), connective tissue diseases like rheumatoid arthritis or lupus, acid reflux (GERD), and genetic factors. In many cases, particularly with IPF, no clear cause is ever identified.

COPD causes center most heavily on long-term cigarette smoking, though as noted above, not all smokers develop COPD and not all COPD patients are smokers. Other contributors include secondhand smoke, air pollution, occupational dust and fumes, and Alpha-1 Antitrypsin Deficiency.

‍

What Are the Symptoms, and How Do They Feel Different?

Both conditions cause breathlessness and fatigue, but the experience of each is distinct.

Pulmonary Fibrosis symptoms typically include a persistent dry cough that does not produce mucus, progressive shortness of breath (especially during physical activity), fatigue and weakness, unexplained weight loss, aching muscles and joints, and clubbing of the fingertips, where the tips of fingers and toes become rounded and enlarged, a sign of long-term low oxygen levels. The breathlessness in PF tends to feel like your chest simply will not open wide enough.

COPD symptoms typically include a chronic cough that often produces mucus or phlegm (especially in the morning), wheezing, chest tightness, frequent respiratory infections, and shortness of breath that worsens during exertion and, in advanced stages, at rest. Many people with COPD experience sudden worsening episodes called exacerbations that can require hospitalization.

One key difference patients often notice: in COPD, breathing out is the hardest part. In Pulmonary Fibrosis, breathing in is where the greatest struggle lies. This is a useful clinical distinction, though individual experiences vary.

‍

How Are They Diagnosed?

Neither condition is diagnosed from symptoms alone. Both require a series of tests, and getting the right diagnosis is critical.

For Pulmonary Fibrosis, doctors typically use a High-Resolution CT (HRCT) scan. In advanced Idiopathic Pulmonary Fibrosis specifically, imaging may show a "honeycomb pattern", this is characteristic of the Usual Interstitial Pneumonia (UIP) pattern associated with IPF, but not all forms of pulmonary fibrosis present this way. Pulmonary function tests (PFTs) will show a restrictive pattern, meaning your lungs hold less air than they should. A surgical lung biopsy may sometimes be needed to confirm the diagnosis. Blood tests can help rule out autoimmune causes.

For COPD, the gold-standard diagnostic test is spirometry, a simple breathing test where you blow into a device that measures how much air you can exhale and how fast. A FEV1/FVC ratio below 0.70 confirms the presence of persistent airflow obstruction and is the GOLD standard threshold for a COPD diagnosis. Chest X-rays and CT scans help assess the extent of damage, and an Alpha-1 Antitrypsin test may be ordered.

‍

How Does Each Condition Affect the Lungs Differently?

In Pulmonary Fibrosis, the lung's architecture is destroyed and replaced by scar tissue. Lung volume shrinks, you simply cannot fill your lungs fully. Oxygen has a harder time crossing the scarred tissue into the bloodstream, causing low oxygen levels (hypoxemia) even when breathing seems manageable.

In COPD, lung volume is often larger than normal, because air gets trapped inside damaged air sacs that cannot push it out efficiently. The airways become chronically inflamed and narrowed. Over time in emphysema, the walls between air sacs break down, creating larger but far less efficient pockets. Less surface area means less oxygen exchange.

‍

What Treatments Are Available?

Treating Pulmonary Fibrosis: There is currently no cure for IPF. Three antifibrotic medications are now approved to slow disease progression. Nintedanib (Ofev) and pirfenidone (Esbriet) have been available since 2014, and clinical trials show both meaningfully slow the advancement of scarring. As of 2025, nerandomilast (Jascayd) has received FDA approval for IPF, offering an additional treatment option that can be used alongside or instead of established antifibrotics. None of these medications reverse existing damage, but they give patients more time. Supplemental oxygen is commonly prescribed when blood oxygen levels drop. Pulmonary rehabilitation improves quality of life, and for eligible patients, lung transplantation remains the only option that can significantly extend life.

Treating COPD: COPD treatment focuses on opening up the airways and reducing inflammation. Bronchodilators, inhalers that relax the muscles around the airways, are the cornerstone of treatment, including short-acting inhalers for relief and long-acting inhalers for daily management. Inhaled corticosteroids reduce airway inflammation in some patients. Pulmonary rehabilitation is equally beneficial for COPD. In severe cases, lung volume reduction surgery or endobronchial valves may be considered. Smoking cessation is the single most effective step for slowing COPD progression.

An important nuance on corticosteroids: Systemic corticosteroids (steroids) are specifically harmful in IPF and should be avoided. However, they may benefit other inflammatory lung conditions that also cause fibrosis, such as hypersensitivity pneumonitis, sarcoidosis, and connective tissue disease-related ILD. This is one of the most important reasons why an accurate, specific diagnosis matters so much before any treatment begins.

‍

Can Someone Have Both Conditions at the Same Time?

Yes, and this is more common than many people realize. A condition called Combined Pulmonary Fibrosis and Emphysema (CPFE) occurs when both scarring and air sac damage are present simultaneously. It is seen most often in long-term smokers. CPFE can be particularly challenging to diagnose because the two conditions partially mask each other's effects on pulmonary function tests, making results appear more normal than the actual level of damage warrants. People with CPFE typically experience severely reduced exercise tolerance and a high risk of pulmonary hypertension.

‍

Prognosis: What Does the Future Look Like?

Both conditions are serious and currently incurable, but understanding what to expect can help you plan and advocate for yourself.

Pulmonary Fibrosis, particularly IPF, tends to progress more rapidly. The median survival after an IPF diagnosis has historically been 2–5 years. Encouragingly, antifibrotic therapies are actively improving these outcomes, and newer approvals like nerandomilast represent continued progress. The course is unpredictable, some patients experience gradual decline, others have sudden acute exacerbations.

COPD progresses more slowly in most cases, especially when smoking is stopped and treatment is consistent. Many people with COPD live for decades after diagnosis. The GOLD staging system (Grades 1–4) helps doctors and patients understand disease severity and guide treatment decisions. With good management, quality of life can remain relatively high for many years.

‍

Questions to Ask Your Doctor

• Is my breathlessness caused by restriction (difficulty breathing in) or obstruction (difficulty breathing out)?
• Do I need a CT scan or a spirometry test, or both?
• Have autoimmune or occupational causes been ruled out?
• Which specific type of pulmonary fibrosis do I have, and does that affect which treatments are appropriate?
• What medications are right for my diagnosis? (And if steroids are being considered, have we confirmed these are safe for my specific condition?)
• Should I be referred to a pulmonologist who specializes in interstitial lung disease?
• Is pulmonary rehabilitation right for me?
• Am I eligible for any clinical trials, including trials of newer antifibrotic therapies?

‍

The Bottom Line

Pulmonary Fibrosis and COPD both affect the lungs' ability to do their most essential job, but they do so in very different ways. PF stiffens and shrinks the lungs through scarring. COPD obstructs and traps air through airway damage and destroyed air sacs. The symptoms overlap enough to cause confusion, but the diagnosis, the treatment, and the lived experience of each condition differ significantly.

If you have been told you might have one of these conditions, or if you are living with a confirmed diagnosis, connecting with a specialist pulmonologist, joining a patient community, and asking questions at every appointment are among the most powerful things you can do.

‍

Disclaimer:

This article is for informational purposes only and does not constitute medical advice. mama health offers information and support and does not replace a doctor. The content is based on published research and clinical guidelines available at the time of writing. Always consult a qualified healthcare professional for diagnosis, treatment decisions, and questions about your individual health. mama health does not provide medical diagnoses or treatment recommendations

‍